PHASE II STUDY OF IMATINIB MESYLATE AS THERAPY FOR PATIENTS WITH SYSTEMIC MASTOCYTOSIS

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003–2005 in phase II clinical trial with ima...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Vega-Ruiz, Arturo, Cortes, Jorge E., Sever, Matjaz, Manshouri, Taghi, Quintás-Cardama, Alfonso, Luthra, Raja, Kantarjian, Hagop M., Verstovsek, Srdan
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184059/
https://ncbi.nlm.nih.gov/pubmed/19193436
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2008.12.020
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars